Der nächste 1000 Prozenter! Hier! - 500 Beiträge pro Seite

[Killerbabe]

Es gibt sie noch, die 1000% Aktien (siehe Primacom und co.)
Es gibt aber auch noch welche, die stehen grad am Anfang der 1000 Prozent.
Eine dieser Aktien dürfte die amerikanische Neose Technologies Inc. ( WKN: 899410) .
Dieser Wert hat vor kurzem erst ein Alltime-Low markiert und ist seitdem schon kräftig angezogen. Kursziele von 4,50 Dollar (100 %) dürfte auf kurze Sicht locker drin sein, der Wert könnte aber ohne weiteres bis auf 7 Dollar steigen (siehe W-Formation), wenn dann für die biopharmazeutische Schmiede aus den USA alles nach Plan läuft, können ganz leicht Kurse über der 14 Dollar Marke angepeilt werden!

Homepage des Konzerns: www.neose.com

Neose is a biopharmaceutical company using its enzymatic technologies to develop proprietary drugs, focusing primarily on therapeutic proteins. We believe that our core enzymatic technologies, GlycoAdvance® and GlycoPEGylation™, improve the drug properties of therapeutic proteins by building out, and attaching polyethylene glycol (PEG) to, carbohydrate structures on the proteins. We are using our technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed by our partners. We expect these modified proteins to offer significant advantages, including less frequent dosing and possibly improved efficacy, over the original versions of the drugs now on the market, as well as to meet or exceed the pharmacokinetic profile of next-generation versions of the drugs now on the market. We believe this strategy of targeting drugs with proven safety and efficacy allows us to lower the risk profile of our proprietary development portfolio as compared to de novo protein drug development.

Our proprietary drug development portfolio currently consists of two therapeutic protein candidates. GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and is approved for sale in major markets around the world for treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Our second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor (G-CSF) that we are co-developing with BioGeneriX AG, a company of the ratiopharm Group. G-CSF is prescribed to stimulate production of neutrophils (a type of white blood cell) and is approved for sale in major markets around the world for treatment of neutropenia associated with myelosuppressive chemotherapy. .

[gs231]

killerbabe, hallo,

ich mal 200 gekauft zur probe.
wir müßen ganz schön werbung für den wert machen, ist bei uns unbekannt.
wenn sich was bewegt kauf ich jederzeit nach.

gruß gerd

p.s. danke für den tip

[Killerbabe]

Aktie vorbörslich (15.12.2005) schon 6,5% im Plus!


Weitere News zu Neose:

Neose and Novo Nordisk Expand Agreement



HORSHAM, Pa., Dec. 15 /PRNewswire-FirstCall/ -- Neose Technologies, Inc. (Nasdaq: NTEC) today announced the expansion of its research and development activities under its license agreement with Novo Nordisk A/S (NYSE: NVO) entered into in November 2003 to use Neose`s GlycoPEGylation(TM) technology to develop a next-generation version of a therapeutic protein currently marketed by Novo Nordisk. The expansion of the agreement will result in additional research and development funding to Neose, as well as the potential for additional milestone payments.

"We are pleased with the expansion of this agreement as it not only demonstrates the progress made to date, but reinforces the commitment of Novo Nordisk and Neose to this strategic partnership," said C. Boyd Clarke, Neose chief executive officer and chairman.

About Novo Nordisk A/S

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 21,600 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk`s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol `NVO`. For more information, visit novonordisk.com.

About Neose Technologies, Inc.

Neose is a biopharmaceutical company using its proprietary enzymatic technologies to develop improved drugs, focusing primarily on therapeutic proteins. Neose uses its GlycoAdvance(R) and GlycoPEGylation(TM) technologies to develop improved versions of drugs with proven safety and efficacy. Neose intends to apply its technologies to products it is developing on its own and to products it co-develops and co-owns with others. It also expects to make its technologies available, through strategic partnerships, to improve the products of other parties. Neose`s first two proprietary candidates are NE- 180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG- GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).

CONTACTS:

Neose Technologies, Inc.

A. Brian DavisSr. Vice President and Chief Financial Officer
[phone]

Barbara Krauter
Manager, Investor Relations
[phone]

For more information, please visit http://www.neose.com.

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that we will not receive the additional milestone payments. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose`s Annual Report on Form 10-K for the year ended December 31, 2004, entitled "Factors Affecting the Company`s Prospects" and discussions of potential risks and uncertainties in Neose`s subsequent filings with the SEC.

SOURCE Neose Technologies, Inc.
-0- 12/15/2005
/CONTACT: A. Brian Davis, Sr. Vice President and Chief Financial Officer,
[phone], or Barbara Krauter, Manager, Investor Relations,
[phone], both of Neose Technologies, Inc./
/Web site: http://www.neose.comhttp://www.novonordisk.com /
(NTEC NVO)

CO: Neose Technologies, Inc.; Novo Nordisk A/S
ST: Pennsylvania, Denmark
IN: HEA MTC BIO
SU: LIC

JT
-- PHTH024 --
7961 12/15/200516:01 ESThttp://www.prnewswire.com